IE 11 is not supported. For an optimal experience visit our site on another browser.

Complete Genomics Files Registration Statement for Proposed Offering of Common Stock

/ Source: GlobeNewswire

MOUNTAIN VIEW, Calif., May 10, 2011 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the underwritten public offering of 4,500,000 shares of its common stock, or up to 5,175,000 shares if the underwriters exercise their over-allotment option. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc. 

Jefferies & Company, Inc. and UBS Investment Bank are acting as joint book-running managers, with Baird and Cowen and Company acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of Jefferies & Company, Inc. at 520 Madison Avenue, New York, NY 10022, Attention: Syndicate Prospectus Department, or via telephone at (888) 449-2342, or from the prospectus department of UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department, or via telephone at (888) 827-7275.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Complete Genomics

Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines our proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this innovative, end-to-end, outsourced solution as CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research.

The Complete Genomics logo is available at

CONTACT: Complete Genomics, Inc. Scott Sandler Investor Relations (650) 943-2788 ssandler@completegenomics.com